Your browser is no longer supported. Please, upgrade your browser.
PHIO Phio Pharmaceuticals Corp. daily Stock Chart
PHIO [NASD]
Phio Pharmaceuticals Corp.
Index- P/E- EPS (ttm)-16.25 Insider Own0.30% Shs Outstand1.77M Perf Week0.00%
Market Cap10.57M Forward P/E- EPS next Y-2.10 Insider Trans0.00% Shs Float4.39M Perf Month23.42%
Income-9.10M PEG- EPS next Q-0.73 Inst Own20.90% Short Float1.37% Perf Quarter-23.21%
Sales0.00M P/S- EPS this Y66.40% Inst Trans- Short Ratio0.15 Perf Half Y-68.67%
Book/sh6.76 P/B0.33 EPS next Y90.00% ROA-82.10% Target Price- Perf Year-90.94%
Cash/sh2.82 P/C0.79 EPS next 5Y- ROE-104.30% 52W Range1.60 - 26.34 Perf YTD-76.18%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-84.33% Beta1.93
Dividend %- Quick Ratio7.00 Sales past 5Y- Gross Margin- 52W Low158.01% ATR0.23
Employees11 Current Ratio7.00 Sales Q/Q- Oper. Margin- RSI (14)83.29 Volatility12.75% 11.16%
OptionableNo Debt/Eq0.00 EPS Q/Q76.80% Profit Margin- Rel Volume252.50 Prev Close2.24
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume394.01K Price4.13
Recom- SMA2081.89% SMA50100.92% SMA200-51.92% Volume48,837,777 Change84.29%
May-29-20 08:00AM  Phio Announces Positive In Vivo Data on the Intratumoral Use of INTASYL Compounds Showing Strong Antitumor Activity PR Newswire +84.29%
05:38AM  PHIO: Intasyl Advantage vs. Gene Editing Zacks Small Cap Research
May-14-20 04:05PM  Phio Presents Data on INTASYL as an Alternative to Genetic Modification to Improve Cell-based Immunotherapy at ASGCT 2020 PR Newswire
May-12-20 04:38PM  Phio Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update PR Newswire -5.36%
May-04-20 07:30AM  Phio to Present at Upcoming Medical Meetings and Investor Conference in Spring 2020 PR Newswire +7.53%
Apr-07-20 06:05AM  PHIO: Collaborations Provide Several Options Zacks Small Cap Research
Apr-02-20 12:15PM  Phio Pharmaceuticals Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market PR Newswire
Mar-31-20 12:11PM  Phio Pharmaceuticals Announces $4.0 Million Registered Direct Offering Priced At-the-Market PR Newswire -19.91%
07:30AM  Phio Announces Positive New Data Validating the INTASYL Immunotherapy Platform's Ability to Develop Novel Compounds Capable of Inhibiting Cancer Tumor Growth PR Newswire
Mar-26-20 05:33PM  Phio Pharmaceuticals Reports Year End 2019 Financial Results and Provides Business Update PR Newswire
Mar-11-20 08:03AM  The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment Benzinga
Mar-10-20 05:06PM  Phio Pharmaceuticals and Helmholtz Zentrum München Announce Collaboration and Option Agreement with Medigene PR Newswire
Feb-13-20 05:20PM  Phio Pharmaceuticals Announces Closing of $8.0 Million Underwritten Public Offering PR Newswire
Feb-12-20 09:18AM  The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data Benzinga +6.67%
Feb-11-20 09:15AM  Phio Pharmaceuticals Announces Pricing of $8.0 Million Underwritten Public Offering PR Newswire -57.27%
Feb-10-20 08:00AM  Phio Pharmaceuticals Announces Compliance with Nasdaq Listing Requirements PR Newswire -10.47%
Feb-06-20 12:30PM  Phio Pharmaceuticals Announces Closing of $1.74 Million Registered Direct Offering Priced At-the-Market PR Newswire
Feb-05-20 09:00AM  Phio Pharmaceuticals Announces $1.74 Million Registered Direct Offering Priced At-the-Market PR Newswire -13.16%
Jan-14-20 12:55PM  Phio Pharmaceuticals Announces Reverse Stock Split PR Newswire +6.72%
Jan-06-20 07:30AM  Phio Pharmaceuticals to Present at Biotech Showcase 2020 PR Newswire +9.67%
Dec-13-19 08:00AM  Phio Pharmaceuticals Announces Adjournment of Special Meeting of Stockholders PR Newswire -12.27%
Nov-21-19 07:30AM  Phio Pharmaceuticals and Karolinska Institutet Expand Collaboration to Develop Self-Delivering RNAi Immunotherapies for Treating Solid Tumors PR Newswire +13.10%
Nov-20-19 05:30PM  Phio Pharmaceuticals Announces Closing of Public Offering of Common Stock PR Newswire -13.91%
Nov-19-19 07:56AM  The Daily Biotech Pulse: Therapix To Reverse Merge With CBD Company, Crispr Gene Editing Therapy Readout Benzinga
Nov-18-19 07:00AM  Phio Pharmaceuticals Announces Pricing of $1.0 Million Public Offering of Common Stock PR Newswire -26.99%
Nov-13-19 04:11PM  Phio Pharmaceuticals Announces Proposed Public Offering of Common Stock PR Newswire -5.17%
11:29AM  Does Phio Pharmaceuticals Corp. (NASDAQ:PHIO) Have A Particularly Volatile Share Price? Simply Wall St.
08:05AM  PHIO: Third Quarter 2019 Financial & Operational Update Zacks Small Cap Research
Nov-12-19 07:45AM  Phio Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Business Update PR Newswire -9.41%
Oct-29-19 08:05AM  Phio Pharmaceuticals to Highlight Self-delivering RNAi Technology at SITC 2019 PR Newswire
Oct-11-19 08:00AM  Phio Pharmaceuticals Announces Adjournment of 2019 Annual Meeting of Stockholders PR Newswire -6.52%
Sep-09-19 07:10AM  Phio Pharmaceuticals Announces Research Collaboration with Carisma Therapeutics to Evaluate its Self-Delivering RNAi Technology to Enhance Macrophage-Based Adoptive Cell Therapy PR Newswire -9.25%
Sep-03-19 07:10AM  Phio Pharmaceuticals to Present at the H.C. Wainwright 21st Annual Healthcare Conference PR Newswire
Aug-26-19 11:30AM  PHIO: Overcoming Immune Checkpoints Zacks Small Cap Research
Aug-15-19 07:05AM  Phio Pharmaceuticals and Helmholtz Zentrum München to Collaborate on Novel Targets for the Use of Self-Delivering RNAi In T Cell and NK Cell Adoptive Cell Therapy Therapeutics PR Newswire
Aug-12-19 05:10PM  Phio Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Business Update PR Newswire
Jun-12-19 10:30AM  PHIO: Two Compounds Entering Clinic in 2020 Zacks Small Cap Research
May-20-19 07:05AM  Phio Pharmaceuticals to Present at Sachs Associates 5th Annual Immuno-Oncology BD&L and Investment Forum PR Newswire
May-14-19 05:15PM  Phio Pharmaceuticals Reports First Quarter 2019 Financial Results and Corporate Highlights PR Newswire +6.35%
Apr-22-19 10:15AM  PHIO: Activation in the Tumor Microenvironment Zacks Small Cap Research
Apr-12-19 09:32AM  After name change, Phio Pharma 'reinvents' gene-silencing pipeline American City Business Journals
Apr-10-19 07:05AM  Phio Pharmaceuticals Appoints Dr. John Barrett as Chief Development Officer PR Newswire
Mar-28-19 07:05AM  Phio and Glycostem to Collaborate on Use of its sd-rxRNA® platform and Glycostem's oNKord® Cell Therapy Products for the Next Generation of Natural Killer Cell-based Immunotherapy for Cancer Treatment PR Newswire
Mar-27-19 05:20PM  Phio Pharmaceuticals Reports Fourth Quarter and Year End 2018 Financial Results and Corporate Highlights PR Newswire
Mar-25-19 07:05AM  Phio Pharmaceuticals to Present Poster on the Use of Self-Delivering RNAi in Immuno-oncology at the AACR Annual Meeting 2019 PR Newswire +7.17%
Feb-15-19 07:15AM  Phio Pharmaceuticals Appoints Gerrit Dispersyn as New Chief Executive Officer Effective March 1 PR Newswire
Dec-18-18 07:05AM  Phio Pharmaceuticals to Present at Biotech Showcase 2019 in San Francisco PR Newswire
Dec-04-18 07:05AM  Phio Pharmaceuticals to Present at the Tumor Targeted Lymphocytes Summit in Boston on December 13 PR Newswire
Dec-03-18 11:30AM  PHIO: Soldiering On as We Wait for Bids Zacks Small Cap Research
Nov-19-18 07:00AM  RXi Pharmaceuticals Corporation Changes Name to Phio Pharmaceuticals Corp. PR Newswire
Phio Pharmaceuticals Corp., a biotechnology company, focuses on discovering and developing immuno-oncology therapeutics to treat cancer in the United States. The company's lead product candidate is RXI-109, an sd-rxRNA that reduces the expression of connective tissue growth factor, a critical regulator of several biological pathways involved in fibrosis, including scar formation in the skin and eye. The company also develops Samcyprone, a topical formulation of the small molecule diphenylcyclopropenone for the clearance of common warts; and RXI-231, an sd-rxRNA compound targeting tyrosinase for use as a cosmetic ingredient that enhances the appearance of uneven skin tone and pigmentation. In addition, it develops RXI-109 that reduces the progression of retinal scarring. The company has collaborations with the Gustave Roussy and Medigene AG, as well as with Helmholtz Zentrum Munchen. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.